drugset / Trial / NCT00186121

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

NCT00186121

Phase 2 Completed 35 enrolled Stanford University AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the antitumor activity, toxicity, and effectiveness of the combination of goserelin (Zoladex) and anastrozole (Arimidex) in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of the breast.

Timeline

Start
2000-10
Primary completion
2013-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Goserelin Other / unclassified 3.6 mg Subcutaneous

Indications